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Abstract
The purpose of this paper is to conduct a review of studies on cystoid macular edema published in the last seven years. Cystoid macu-
lar edema is a major cause of loss of visual acuity. It is the final common pathway of many diseases and can be caused by numerous 
processes including inflammatory, vascular, adverse drug reactions, retinal dystrophy or intraocular tumors.  These processes disrupt the 
blood-retinal barrier, with fluid extravasation to the macular parenchyma. Imaging tests are essential for both detection and monitoring 
of this pathology. Fluorescein angiography and autofluorescence show the leakage of liquid from perifoveal vessels into the tissue where 
it forms cystic spaces. Optical coherence tomography is currently the gold standard technique for diagnosis and monitoring. This allows 
objective measurement of retinal thickness, which correlates with visual acuity and provides more complete morphological information. 
Based on the underlying etiology, the therapeutic approach can be either surgical or medical with anti-inflammatory drugs. We found that 
disruption of the blood-retinal barrier for various reasons is the key point in the pathogenesis of cystoid macular edema, therefore we 
believe that studies on its treatment should proceed on this path.
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Introduction
Cystoid macular edema (CME) is the accumulation of fluid in 
the retina between the outer plexiform layer and the inner 
nuclear layer around the fovea, which results in the formation 
of cysts. In the long term, these cysts may coalesce into lar-
ge cystic spaces, irreversibly damaging the central vision. This 
review presents a brief synopsis of the pathophysiology, diag-
nosis, management and treatment of CME. In addition, many 
publications contain information on the CME but not addressed 
globally, and that is what this article is intended to achieve. 
The aim of this publication is to present a review of studies 
published on CME in recent years, to provide a more current 
view as the management of this constantly evolving condition.
Search Strategy and Selection Criteria
A literature search was performed up to July 2014 using the 
MEDLINE database, PubMed, and Google Scholar search ser-
vices with the following key words and word combinations: 
cystoid macular edema, macular edema, CME treatment, CME 
diagnosis, CME etiology, Irvine-Gass syndrome.
A total of 3728 articles were found. After filtering by author cri-
teria (articles published between 2008 and July 2014), English 
or Spanish language, and the condition that they all addressed 
cystoid macular edema as the main theme (pathophysiology, 
diagnosis and treatment) and not merely as a complication 
of another disease), 26 articles were included after a full text 
review. All the abstracts were then carefully divided into subca-
tegories covering topics including pathogenesis, etiology, clini-
cal manifestations, research and treatment of macular edema. 
This review covers systematic reviews, original articles, a letter 
to the editor and an interpretive essay (Figure 1). We did not 
contact other authors for further articles inclusion.
1Instituto de Investigaciones Oftalmológicas Ramón Castroviejo. Universidad Complutense de Madrid. Madrid, Spain.
Figure 1. Flow Diagram Showing the Number of Studies Included in 
and Excluded From the Review.
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Pathophysiology of CME
CME is a common form of response of the retina to different 
insults:
1. Postsurgical CME
Also known as the Irvine-Gass syndrome,1 this is a major cause 
of clinically significant reduced vision after intraocular surgery 
which can occur even in the absence of complications during 
surgery (about 1% of post-surgical CME).2-5 The incidence is hi-
gher (up to 20%)6 after cataract surgery, although it can occur 
after penetrating keratoplasty, glaucoma surgery or YAG laser 
capsulotomy following panretinal photocoagulation. However, 
it has been observed that the use of phacoemulsification sig-
nificantly reduces postoperative CME (0.1-2.35% with this tech-
nique), and in cases where it does develop, it is often limited.3 
CME may be acute (when it appears during the first 4 months 
after surgery), late (if it appears later than 4 months), chronic 
(if it happens after 6 months) or recurrent.3 It usually appears 
between 4 and 12 weeks after cataract surgery, although it can 
occur years later.7,8
The pathogenesis of CME is under discussion, although some 
theories posit the existence of inflammatory factors -prosta-
glandins (PG), leucotriens (LT)- that increase vascular permea-
bility causing fluid accumulation in cysts, or changes in protein 
composition of the vitreous humour, as a result of the surgical 
trauma.2,3,8,9 Also, vitreomacular traction,3,8,9 vitreouveal trac-
tion,3 vitreous incarceration,3 loss of vitreous humour,5 poste-
rior capsule rupture8 or hypotonic vitreous8,9 may contribute to 
the development of a CME and likewise iatrogenic iris injuries,5 
retinal vein occlusions or even the presence of epiretinal mem-
branes. However, it has been observed that posterior vitreous 
detachment could be a protective factor.10
The incidence of CME after cataract surgery varies depending 
on the type of procedure, the surgeon’s experience and the 
patient’s profile (comorbidities such as systemic diseases and 
other eye disorders).8 The most important risk factors associa-
ted with this process include Diabetes Mellitus (DM),7,9 hyper-
tension (HT),5 and old age,9 as well as preexisting conditions 
such as uveitis,7 retinal vein occlusion,5 and the presence of 
epiretinal membranes.3 
2. Uveitis
CME is the most common complication of uveitis and the most 
common cause of visual loss in patients with intraocular in-
flammatory diseases.5 Compared to Irvine-Gass Syndrome, 
uveitic CME seems to have a worse prognosis and greater im-
pact on the visual acuity (VA) of affected patients, especially 
older patients or those with concomitant chronic diseases.2 
It typically occurs in patients with an intermediate or poste-
rior uveitic component but can also be found in patients who 
only suffer from HLA-B27-Associated acute anterior uveitis.2,5,7 
It usually appears in patients with autoimmune uveitis (pars 
planitis, birdshot retinochoroidopathy, Vogt-Koyanagi-Harada 
syndrome, Behçet’s disease)5 or infectious (toxoplasmosis),2,5,7 
toxic (associated with rifabutin)2 or idiopathic (sarcoidosis, 
idiopathic vitritis)2 disorders. 
The pathogenesis is not well defined, but it is known that the 
most important mechanism is the loss of integrity of the BRB, 
caused by inflammatory mediators generated by uveitis (inclu-
ding PG, LT, interleukins, tumour necrosis factor alpha, vascu-
lar endothelial growth factor [VEGF]).2,5,7 If edema is caused by 
pars-planitis, it disappears within 6-9 months, and it is possi-
ble to restore vision; however, if it persists beyond this time, 
chronic macular changes occur and the CME will cause perma-
nent vision damage.5,7 Some authors, therefore, recommend 
intensive management, since this achieves long-term visual 
improvement in most patients. In fact, it has been found that 
VA in the first month of follow-up after treatment is similar to 
VA throughout the follow-up period.11
There are two factors that may be associated with a better 
outcome in the long term: good VA at the beginning of the 
treatment (it has been seen that the photoreceptors are capa-
ble of recovering a fraction of visual function with treatment, 
so that patients with less damage at the beginning will reco-
ver their VA better); and lower age (this association with age 
is independent of the duration of uveitis or duration of the 
follow-up).11
3. Laser
CME development or the worsening of an existing CME is a 
complication of panretinal photocoagulation used in the treat-
ment of vascular retinopathy, or after YAG laser posterior cap-
sulotomy.5 It usually occurs between 1 and 5 months after 
the procedure and has been observed to relate more to the 
opening of the posterior capsule than to laser energy.2 It is 
suspected that laser induces the production of inflammatory 
mediators and would also enhance fluid extravasation by in-
creasing the vascular flow to the macula.2,5
4. Retinal vein occlusion
The occlusion of both the central retinal vein and its branches 
is a common cause of CME.5,7,12 The pathogenesis of this disea-
se is not clearly understood. Some authors support the idea 
that thrombotic occlusion of the vein is responsible for the cli-
nical manifestations of CME in this case; others claim that the 
cause is inflammation, but we cannot rule out the possibility 
that both act in a complementary manner.5
In the first case, the vein occlusion causes a rise in intravas-
cular pressure in retinal veins distal to the occlusion site. By 
increasing the hydrostatic pressure, it causes transudation of 
fluid into the extravascular space.5,13 In the second case, on 
the other hand, BRB rupture mediated by cytokines expressed 
in hypoxic retina (VEGF, IL6 or factors derived from the retinal 
pigment epithelium [RPE]) may lead to fluid extravasation.5
There are a number of concurrent processes that can worsen 
vision loss, such as macular haemorrhage2, macular ischae-
mia,2 submacular fluid with secondary damage to the RPE,2 
traction by  epiretinal membranes13 or vitreomacular attach-
ments.5 The development of fluid blood levels in the retina 
is common following obstructive venous retinopathy, although 
this can also be found in many other retinal diseases.5,7 CME 
resulting from either central or peripheral occlusion tends to 
be chronic (> 8 months) and difficult to manage.5,7 Persistent 
CME may be associated with hyperlipidaemia, cardiovascular 
history or vitreomacular adhesions and correlates inversely 
with glaucoma.7
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5. Diabetic retinopathy
Diabetic CME is the leading cause of vision loss in diabetic 
patients.5,7,12,14 The pathogenesis is related to an increase in 
retinal blood flow resulting in extravasation of fluid into the 
parenchyma, but BRB rupture may be more important.5,13 The 
latter seems to be triggered by chronic hyperglycaemia typica-
lly affecting the vessels of these patients, which in turn trig-
gers a series of metabolic events that culminate with increased 
expression of inflammatory cytokines such as VEGF, which can 
change vascular permeability. This whole process is enhanced 
by the presence of partial vitreomacular adhesions caused by 
partial vitreous detachment.5
6. Radiation
CME is a common manifestation in patients who have received 
radiation in the head and neck areas.15 The retinopathy sig-
ns are similar to those in diabetic retinopathy, including CME, 
which is the main cause of vision loss in radiation retinopathy.5 
Its incidence depends on the total dose and daily fraction, but 
CME changes often develop from 30-35 Gray (Gy), usually be-
tween 6 months and 3 years from the beginning of the treat-
ment. Bilateral retinopathy occurs in at least half of patients 
treated with external beam radiation.15
7. Drug reactions
CME can be caused by drugs such as adrenaline, nicotinic acid 
and topical latanoprost (prostaglandin analogue). Topical 2% 
adrenaline may produce cystic changes by reducing blood flow 
to the retina and choroid. The nicotinic acid used for the treat-
ment of hypercholesterolaemia leads to the formation of cystic 
spaces in the inner nuclear layer and outer plexiform layer, 
which are solved by discontinuing the drug.5 It is thought to 
damage the BRB and cause CME, which is angiographically de-
tectable during the early postoperative period in pseudophakic 
patients.15
A case of CME secondary to the use of risperidone has been pu-
blished recently. Its authors believe CME is dose-dependent, as 
it disappears after drug withdrawal. The causative mechanism 
appears to be related to vasodilation of retinal vessels secon-
dary to adrenergic blockade exerted by the drug, although this 
effect has not yet been confirmed in humans.16 Other drugs 
associated with CME are docetaxel,17 paclitaxel,18 tamoxifen,5 
and glitazones.19
8. Retinal dystrophies
CME occurs in 10% of patients with retinitis pigmentosa.5 The 
perifoveal capillaries show increased permeability or reversed 
polarity in degenerating RPE cells.15 It is believed that antibo-
dies may have a role in the pathophysiology of CME.5,7
9. Traction maculopathies
Vitreous traction syndrome is characterized by partial separa-
tion of the peripheral vitreous with persistent adherences to 
the macula.5 The syndrome may include foveal cysts (consi-
dered a prerequisite to the development of a macular hole), 
epiretinal membranes, macular holes and total lamellar thic-
kness and tractional CME. The natural history of the syndro-
me, its prognosis and treatment depend on the size of the 
vitreomacular residual adhesions and consequent macular 
anatomical changes.20
10. Intraocular tumours
CME is associated with tumours such as choroidal nevi, ma-
lignant melanomas, retinal capillary haemangioma or caver-
nous haemangiomas.5 Cystoid changes occur on the tumour 
and at sites distant from it because of the lack of retinal 
oxygenation.15
Diagnosis
CME is associated with two fundamental processes, the accu-
mulation of abnormal extracellular fluid and the formation of 
cystic spaces. There are various diagnostic tests to confirm the-
se findings. Some, like fundus fluorescein angiography (FA) or 
autofluorescence imaging, are geared to detect abnormalities 
in the BRB.7 Others, like optical coherence tomography (OCT), 
are aimed at detecting retinal thickening.7,14 The detection of 
CME in these tests does not always mean it is clinically sig-
nificant, as clinical CME is defined as a decrease in vision to 
20/40 or less that is detectable by FA or OCT.2 The most common 
symptoms and signs in CME are blurring or central vision loss, 
as well as edema and painless swelling of the retina. Most 
cases are asymptomatic and are only detected by the imaging 
techniques mentioned.2
1. OCT
OCT is based on low-coherence interferometry, typically using 
near-infrared light. Relatively long-wavelength light can be 
used to penetrate the scattering medium and thus obtain hi-
gh-resolution cross sections of the sensory retina, providing 
morphological information on the CME.12 This allows the phy-
sician to make accurate retinal13,21 and choroid thickness me-
asurements.7,13
Measuring retinal thickness is crucial since there is a negative 
correlation between thickness in the centre of the macula and 
VA.13,14 This is because the neuroretina requires the bipolar cells 
to be intact in order to maintain a connection between the pho-
toreceptors and ganglion cells, so that when the accumulation 
of fluid in cysts exceeds the elasticity of bipolar cells, the axons 
break up and the neural transmission is interrupted.14 Some 
authors assert that when the cysts fuse and separate the inner 
and outer layers of the retina, the loss of neural transmission 
may not lead to any improvement of VA, even when CME is 
resolved, which is also associated with atrophic changes and 
thinning of the macula, both observable with OCT.22
Choroidal thickness is increasingly being seen as important in 
some pathologies causing CME, as in the case of DM, where 
some authors have reported increased thickness of the choroid 
directly proportional to the degree of diabetic retinopathy.23
OCT is an objective test that is highly sensitive regardless of 
the etiology of the CME (95% sensitivity for detection of defi-
nite CME, when compared to  fluorescein angiography (44%), 
in series where questionable grades were interpreted as non-
CME cases; 83% sensitivity when compared to AFG (74%) in 
series where questionable grades were interpreted as posi-
tive CME cases).12 The great advantage of this technique is 
that it is fast, non-invasive and does not cause discomfort to 
the patient.12,21 OCT is considered the current gold standard 
for CME diagnosis and is also used for monitoring treatment 
(Figure 2).3,7,12,14,21
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2. Fluorescein angiography (FA)
When FA is used to examine the fundus, the circulation in the 
retina and choroid can be studied by injecting a contrast that 
shines when stimulated with light in the blue wavelength range 
between 265 and 490nm (fluorescein). This provides functional 
and qualitative information that enables the physician to loca-
te and describe the pattern of vascular leakage. FA shows the 
extravasation of fluid from the perifoveal capillaries in the early 
stages and the accumulation of contrast in a petaloid, honey-
comb or diffuse pattern in later stages.3,12,24 However, it has the 
disadvantage of being invasive and its interpretation depends 
on the physician (Figure 3).12
Contrast extravasation does not always imply an accumulation 
of intraretinal fluid, as there may be situations where the liquid 
does not accumulate despite the contrast because it is esca-
ping from the vessels at the same rate as it is being pumped in 
by the RPE. The opposite situation is also possible; for exam-
ple, there could be an accumulation of fluid without hyperfluo-
rescence. This happens when the escape point is very small, 
so that the molecules escape slowly and disperse quickly in 
the cystic space and are thus not detected by the FA in the 
standard period of time (10 minutes).12
Diagnosis can also be difficult in cases where it is not possible 
to discern whether the fluid observed belongs to cysts in the 
retina or other pathological conditions of the retina where con-
trast extravasation occurs (such as choroidal neovasculariza-
tion or RPE alteration).12 This test is used for clinical diagnosis 
of CME as well as to perform the treatment. A relationship has 
been observed between loss of VA and the presence of cysts, 
although there is no proven relationship between VA and the 
distance of the cysts from the fovea.3,7,12,13
3. Autofluorescence
Autofluorescence occurs through the absorption of short wave-
length light by the lipofuscin from the RPE cells and emission 
at a longer light wavelength. This is due to the presence of 
lipofuscin (an autofluorescent substance that increases with 
age, cell stress and oxidative damage) in the lysosomes of such 
cells. When RPE is not viable autofluorescence from those cells 
disappears. Normally RPE autofluorescence is masked by the 
pigments in the outer plexiform membrane; however, this does 
not happen in CME, where the fluid accumulating in the cyst 
redistributes Henle fibres in that layer, allowing us to observe 
the natural fluorescence of the RPE.24 This technique can be 
used to monitor patients with CME and could be an alternative 
for patients who have a history of adverse reactions when fluo-
rescein is injected (81% sensitivity, 69% specificity).24 Also, it is 
a minimally invasive test and is quick to perform.7,24
However, this technique has some disadvantages: firstly, the 
lens (which opacifies with age) interferes with the fluorescence 
of the RPE because it is excited at a wavelength similar to the 
one on which this technique operates, so that high contrast 
images cannot be obtained. Secondly, it is not considered an 
accurate way to assess the severity of CME, although it can be 
Figure 2. OCT Scans of the Macula. (A) Cystoid macular edema secondary to diabetes mellitus type-II, showing the presence of cysts within the 
inner nuclear layer. The absence of the normal foveal depression can also be observed. (B) Morphological recovery after photocoagulation treat-
ment and systemic control of the patient’s diabetes. (C,D) Three-dimensional reconstruction of the fovea before (C) and after (D) the treatment.
Figure 3. Macular Hyperfluorescence Observed with Fluorescein 
Angiography in a Diabetic Patient. Petaloid pattern secondary 
to contrast leakage from perifoveal capillaries to the cystic spa-
ces. There are also panphotocoagulation scars all around the 
retina.
Lengend: Original images from the image bank of the “Instituto de Investigaciones Oftalmológicas Ramón Castroviejo (UCM)”.
Lengend: Original images from the image bank of the “Instituto de Investiga-
ciones Oftalmológicas Ramón Castroviejo (UCM)”.
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used as an alternative when it is not possible to perform the 
OCT. Another limitation is the presence of concomitant patholo-
gy of retinal layers and the RPE, because it interferes with the 
autofluorescence pattern. Finally, this test is not useful if the 
patient has a non-cystic macular edema because these scatter 
less pigment.24
Management and Prevention
1. Anti-nflammatory drugs (NSAIDs)
In aphakic or pseudophakic CME, the occurrence of intraocu-
lar inflammation with synthesis of prostaglandins results in 
disruption of the tight junctions of the perifoveal retinal ca-
pillaries.7 capillaries. NSAIDs inhibit the conversion of arachi-
donic acid to endoperoxides and thus inhibit the synthesis of 
PG, which reduces fluid leakage from capillaries.2,7 In addition, 
some NSAIDs, such as diclofenac, act on other mediators to 
inhibit the formation of lipoxygenase products, which are re-
quired for the production of the PG.25
NSAIDs are currently available in different formulations and ad-
ministration routes, such as oral, topical or intravitreal. Increa-
sed ocular penetration of NSAIDs has been observed when they 
are administered topically rather than systemically.3 The most 
widely used topical NSAIDs are 0.5% ketorolac, 1% indome-
thacin and 1% diclofenac, which are useful for treatment and 
prevention of postsurgical CME.26,27 In fact, there are studies 
suggesting that NSAIDs are more effective than corticosteroids 
in preventing postoperative CME,9,10 especially if administered 
between 1 and 3 days before surgery.10 They are also useful 
for prevention of angiographic edema, although the decrease 
in retinal thickness and edema does not always correlate with 
an improvement in VA.3,28
The main complications of this treatment include, in descen-
ding order of frequency, irritation, burning, stinging, ocular 
discomfort, conjunctival injection, punctate keratitis, corneal 
melting, mydriasis, delayed wound healing, hypersensitivity 
and allergic reactions.9,10 When combined with intravitreal ste-
roid therapies or with anti-VEGF injections, these drugs can en-
hance the effect of the former in chronic pseudophakic CME.29
2. Glucocorticoids
Glucocorticoids inhibit the production of PG and LT by inhibiting 
the phospholipase A2 enzyme.2,30 Besides their vasoconstric-
tor properties, steroids reduce intracellular and extracellular 
edema and hijack T lymphocytes from circulation, inhibiting 
recruitment and cytotoxic activity. They also suppress the acti-
vity of macrophages and polymorphonuclear cells and reduce 
lymphokine production.7
In the case of post-surgical CME, no difference has been found 
in the control of inflammation when comparing the power of 
the corticosteroids employed. It has not been proven that ste-
roids increase bleeding time after eye surgery, but it is some-
thing to be aware of.10
Corticosteroids can be administered by different routes:
• Topical steroids: prednisolone acetate lipophilic suspen-
sions easily penetrate through the intact corneal epithelium 
and reach the anterior chamber, achieving higher concentra-
tions than hydrosoluble suspensions such as dexamethasone.31 
The power in descending order is: 0.1% dexamethasone, 1% 
prednisolone, 0.1% fluorometholone, 1% rimexolone, 0.5% lo-
teprednol and 1% medrysone. These properties are useful in 
the treatment of CME caused by chronic iridocyclitis or iritis.7 
Ocular complications of topical steroids include an increase in 
intraocular pressure (IOP), posterior subcapsular cataract, in-
creased incidence of ocular viral infections, mydriasis, ptosis 
and eyelid skin atrophy.15
• Periocular sub-Tenon injection: penetrates through the scle-
ra generating a maximum and lasting response. This route of 
administration allows physicians to use water soluble steroids. 
One of the possible risks is eyeball penetration. In addition, 
it is contraindicated in certain groups of patients such as ste-
roid-induced glaucoma, hypersensitivity to any of its compo-
nents, necrotizing scleritis and active ocular toxoplasmosis.15
• Intravitreal Injection: triamcinolone acetonide is the most 
commonly used drug. It is especially used in difficult-to-treat 
cases such as refractory pseudophakic CME,3 uveitic CME and 
CME secondary to venous occlusion.29 It has the same risks 
and contraindications as the foregoing routes; it also includes 
increased risk of developing glaucoma,8 and the possibility of 
retinal detachment,5,7 endophthalmitis,2,5 lenticular trauma and 
recurrence after discontinuation of injections.5 Furthermore, it 
has been observed that most patients do not show sustained 
improvement over time despite receiving multiple injections.2,5 
Intravitreal implants are currently being developed; these re-
lease the drug at a steady rate and could be an alternative in 
patients who are poorly controlled or are intolerant of repeated 
injections, systemic steroids or immunosuppressive agents.32,33 
It has been shown that they are not toxic and they maintain 
constant intraocular levels of the drug for a long period of time 
(3-6 months, peaking within the first week).34 For instance, in-
traocular implants help reduce uveitic recurrences, reduce the 
need for adjuvant therapy and improve VA through the reduc-
tion of retinal thickness, as has been demonstrated by OCT 
studies.35 However, there can be side effects, such as increa-
sed IOP,36 cataract,37,38 retinal detachment,39 and endophthalmi-
tis.37,38 The other drawback of these devices is that they must 
be surgically removed once they cease to exert their effect. 
Researchers are therefore developing new biodegradable devi-
ces that gradually dissolve into the vitreous, avoiding the risks 
entailed in surgical removal.40,41
• Systemic steroids: especially indicated in CME produced by 
pars planitis or birdshot chorioretinopathy. Short-term effects 
can include peptic ulcer, aseptic necrosis of the femoral head 
and disturbances such as euphoria, insomnia and psychosis. 
Possible long-term adverse effects include osteoporosis, Cus-
hingoid state, tuberculosis, myopathy, suppression of pitui-
tary-adrenal axis and the worsening of preexisting HT or DM. It 
is therefore very important to monitor the patient, especially 
in the first two weeks. Systemic steroids are most commonly 
administered orally or parenterally.15
3. Immunosuppressive agents
In cases of severe uveitis requiring long-term treatment with 
medium to high doses of corticosteroids, the use of immunosu-
ppressive drugs should be considered, since studies show that 
intravitreal methotrexate can reduce the CME and improve VA.2,42
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4. Carbonic anhydrase inhibitor: Acetazolamide
Carbonic anhydrase inhibitors increase the transport of fluid 
through the RPE from the subretinal space to the choroid, 
reducing edema.3,43 They seem to be especially useful in the 
treatment of CME secondary to retinitis pigmentosa, althou-
gh these drugs have been used in studies of postoperative 
CME.3,8,44 Eighty per cent of patients treated with acetazolami-
de have demonstrated VA improvement; however, the thera-
peutic effect appears to be independent of the reduction of 
macular edema.44
Usually, an initial dose of 500 mg/day is administered for at 
least a month, and then the dose will be modified depending 
on the response.7 The most common side effects include numb-
ness, fatigue, depression and loss of libido.3
5. Anti-VEGF
Anti-VEGF drugs block the effects of this inflammatory factor, 
thereby inhibiting its function (endothelial joint relaxant) and 
reducing vascular permeability and leakage of fluid into the ma-
cula.45 This group of drugs includes pegaptanib (selective), ra-
nibizumab and bevacizumab (nonselective). While ranibizumab 
has been proven to be safe and beneficial for VA improvement 
by reducing retinal thickness in patients with pseudophakic 
CME,5,46 bevacizumab has not yet been approved for ophthalmic 
use. In fact, it is still being studied for the treatment of CME 
of inflammatory origin (especially secondary to retinal central 
vein occlusion, uveitis or after cataract surgery).47-50
These intravitreal anti-VEGFs are promising for the treatment 
of refractory CME; however, the Food and Drug Administration 
(FDA) has not yet approved them for this pathology. Studies 
on diabetic macular edema show benefits in VA when using 
anti-VEGFs. However, a clear improvement has not been seen 
in VA and macular thickness in uveitic CME, where it is belie-
ved that these drugs have a transient, modest and variable 
stabilizing effect.5,47 As in the case of injected steroids, there 
is a high recurrence rate when the treatment is discontinued, 
so it also requires repeated injections (which may lead to en-
dophthalmitis).28 Therefore, studies are currently in progress 
on new routes of administration. However, unlike steroids, 
anti-VEGFs have the advantage of not causing cataract or in-
creasing IOP.47 For all the above reasons, some authors recom-
mend reserving these drugs for cases that are refractory to 
conventional treatments.48
6. Interferon
Interferon plays an important role in the treatment of autoim-
mune diseases (such as Behçet's disease) and appears to be 
useful for reducing intraocular inflammation. Its side effects 
include ‘flu-like’ symptoms, fatigue, hepatotoxicity and psy-
chological disorders.2
7. Somatostatin analogues: octreotide
It has been observed that these drugs reduce edema in 70% of 
persistent uveitic CME cases. This response seems to be related 
to the duration of the CME prior to starting treatment.2
8. Hyperbaric oxygen therapy
Hyperbaric oxygen has been proposed by some authors as the-
rapy for CME due to its potential vasoconstrictor effect, which 
may reduce venous pressure, allowing stabilization of the tight 
junctions of endothelial cells. There are no conclusive studies 
regarding the effectiveness of this therapy.29
9. Photocoagulation
This technique employs a powerful light source to coagula-
te tissue. Several theories have been put forward to explain 
the beneficial effect of laser in patients with CME. On the one 
hand, it appears that cells respond to damage by creating new 
connections in a few weeks, which restores the integrity of the 
RPE.39 On the other hand, an alternative hypothesis suggests 
that laser destroys photoreceptors, thereby reducing the con-
sumption of oxygen in the outer retina. This allows only a little 
oxygen to diffuse from the choroid to the inner retina and thus 
limits hypoxia. All these changes promote vasoconstriction, 
which leads to a reduction of hydrostatic pressure, further re-
ducing the pressure and the diameter of the vessels and hence 
reducing the fluid outflow from the veins. Diabetic macular 
edema and macular edema following occlusion of a retinal vein 
branch thus seem to improve after laser application. However, 
this treatment is not indicated when there is predominance of 
ischaemic maculopathy.51
Panretinal photocoagulation is usually performed after or si-
multaneously with anti-inflammatory steroid treatment, becau-
se inflammation generated by the laser alters the flow and 
thereby the retinal macular function, reducing VA.52,53
Focal laser treatment is used to obliterate microaneurysms 
that cause focal fluid leakage. Grid photocoagulation may re-
duce leakage attributable to abnormalities of dilated macular 
capillaries, with a positive effect on VA and fluorescein ex-
travasation in diabetic CME,7 radiation retinopathy,5 and CME 
secondary to occlusion of a retinal vein branch.7 The main 
collateral damage associated with this treatment is the forma-
tion of scotoma, usually in laser-burnt areas, which disappear 
within a few weeks.52
10. Vitrectomy
This technique is reserved for refractory cases.3 Its usefulness 
in CME lies in its effect of removing vitreoretinal adhesions,5,54 
and inflammatory mediators present in the vitreous humour,5,54 
plus it allows better steroid access to the posterior pole. It is 
useful for CME with vitreo-macular tractions in pseudophakic, 
phakic, or diabetic patients (who have a higher incidence of 
vitreous detachment compared with non-diabetic patients).55 
It is crucial to eliminate the adhesions to resolve this CME, 
and so it is necessary to complete the vitreous detachment; 
this can occur spontaneously or may be achieved by surgery 
(vitrectomy), although recent studies are reporting favourable 
results with pharmacological vitreolysis.20
Compared with laser treatment, vitrectomy appears to impro-
ve VA significantly, especially combined with removal of the 
posterior cortical membrane.5 Some studies have concluded 
that this technique achieves no better results than intravi-
treal triamcinolone administration in pseudophakic patients 
in the long term.8 Despite its effectiveness, vitrectomy can 
lead to complications such as cataracts, retinal detachment, 
vitreous haemorrhage and recurrent glaucoma secondary to 
an increase in IOP.7
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Discussion
When we pooled our findings, we found that CME is a common 
cause of loss of VA for many diseases, regardless of the cause. 
So even if it is a single entity, authors approaching CME from 
different points of view are not agreed on the pathophysiology, 
although they all point in similar directions, such as fluid ex-
travasation to the retina due to loss of BRB integrity or increa-
sed intravascular pressure aided by inflammatory mechanisms. 
However, there must be factors that are not yet known since 
some cases heal spontaneously.3
An understanding of the pathophysiology is essential for effec-
tive treatment, but it is just as important to know the right 
moment to begin the treatment. Avoiding treatment delay is 
crucial to prevent permanent loss of VA associated with irre-
versible tissue damage.
The use of nonsteroidal and steroidal agents appears to reduce 
the incidence of postoperative CME,56 while a relationship has 
been detected between the use of latanoprost after surgery and 
greater disruption of the blood-retinal barrier (BRB);3,5,7 although 
there are studies suggesting that in most patients the CME may 
resolve spontaneously without any treatment after surgery.8
Some authors report that there is little more improvement of 
VA after the first month of treatment.9 Chronicity of CME impe-
des recovery of VA, which leads us to believe that treatment 
should be aggressive especially during the first month. It is 
necessary to establish precisely the time and the circumstan-
ces in which to start treatment, since CME does not develop 
immediately, but after a period of latency.
For purposes of diagnosis and further research, the consensus 
seems to be that for the present OCT is the best test, given the 
following advantages: it is non-invasive, it is more objective 
than other tests, and results are less affected by comorbidities.
Conclusion
In conclusion, fluid extravasation to the retina due to loss of 
BRB integrity or increased intravascular pressure aided by in-
flammatory mechanisms could be the generic factors that take 
place in the diverse pathologies that can lead to a CME. It is 
essential to identify the pathophysiological cause to determine 
the most effective treatment.
For all the foregoing, we believe further research is needed to 
identify the pathophysiological basis of CME so that we can 
develop effective therapeutic algorithms for CME, regardless 
of the cause. For there may not be the adequate improvement 
unless the underlying cause is treated, and indeed, the CME 
could reappear.
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